32 unknown, 26 completed, 15 recruiting, 6 active not recruiting. 44 Phase 1, 24 Phase 2, 17 Phase 3, 8 Phase 4.
Follow Jiangsu Simcere Pharmaceutical Co., Ltd.: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of SIM0689 in Adult Participants With Locally Advanced or Metastatic Solid Tumors SIM0689 for Injection - Neoplasms, Malignant | Phase 1 | Recruiting | Jiangsu Simcere Pharmaceutical Co., Ltd. | 472 | 2026-07-03 | 2026-08-20 |
| Safety and Efficacy of Edaravone Dexborneol Sublingual Tablets for Blood-Brain Barrier Dysfunction in CADASIL Edaravone Dexborneol Sublingual Tablets - CADASIL | Phase 2 | Not yet recruiting | Huashan Hospital | 60 | 2026-07-01 | 2026-07-09 |
| A Phase III, Randomized, Double-blind, Multi-center Trial Comparing Efficacy and Safety of Trilaciclib Versus Placebo in Participants With Limited-stage Small Cell Lung Cancer Trilaciclib, Trilaciclib Placebo, Etoposide Injection - Myelosuppression | Phase 3 | Active not recruiting | Jiangsu Simcere Pharmaceutical Co., Ltd. | 106 | 2026-06-17 | 2026-10-19 |
| SIM0613 in Participants With Advanced Solid Tumors SIM0613 - Advanced Solid Cancer | Phase 1 | Recruiting | Jiangsu Simcere Pharmaceutical Co., Ltd. | 294 | 2026-05-15 | 2026-06-01 |
| A Phase I Study of SIM0532 in Adult Participants With Advanced Solid Tumors SIM0532 Tablets - Histologically or Cytologically Confirmed Advanced Solid Tumors | Phase 1 | Active not recruiting | Jiangsu Simcere Pharmaceutical Co., Ltd. | 346 | 2026-03-31 | 2026-08-11 |
| First in Human Study of SIM0610 in Solid Tumors SIM0610 for Injection - Advanced Solid Tumours, Non-Small Cell Lung Cancer | Phase 1 | Recruiting | Jiangsu Simcere Pharmaceutical Co., Ltd. | 260 | 2026-01-19 | 2026-01-23 |
| A Phase I, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single Ascending Doses of SIM0811 Injection in Healthy Chinese Adult Participants SIM0811, Placebo - Health, Subjective | Phase 1 | Completed | Jiangsu Simcere Pharmaceutical Co., Ltd. | 64 | 2026-01-12 | 2026-10-22 |
| An Open-Label Drug Interaction Clinical Study to Evaluate Itraconazole, Rifampin, Midazolam and SIM0270 in Chinese Healthy Adult Participants SIM0270, itraconazole, Rifampin - Healthy Adult Participants | Phase 1 | Recruiting | Jiangsu Simcere Pharmaceutical Co., Ltd. | 60 | 2026-01-05 | 2026-01-22 |
| A Phase Ib/III Study of Suvemcitug Plus FTD/TPI in Participants With Refractory Metastatic Colorectal Cancer Suvemcitug injection, trifluridine/tipiracil tablets, Suvemcitug placebo injection, trifluridine/tipiracil tablets - Refractory Metastatic Colorectal Cancer | Phase 3 | Recruiting | Jiangsu Simcere Pharmaceutical Co., Ltd. | 464 | 2025-11-12 | 2026-01-22 |
| A Phase I Study of SIM0609 in Adult Participants With Locally Advanced/Metastatic Solid Tumors SIM0609 for injection, dose expansion of SIM0609 in CRC, dose expansion of SIM0609 in GC/GEJC cohort - Advanced Solid Cancer | Phase 1 | Recruiting | Jiangsu Simcere Pharmaceutical Co., Ltd. | 232 | 2025-11-07 | 2025-12-05 |
| A Phase 2 Study to Evaluate the Efficacy, Safety of SIM0278 in Subjects With Moderate to Severe Atopic Dermatitis SIM0278 injection, Placebo - Atopic Dermatitis (AD) | Phase 2 | Not yet recruiting | Jiangsu Simcere Pharmaceutical Co., Ltd. | 184 | 2025-10-27 | 2025-09-23 |
| A Phase I Study of SIM0686 in Participants With Locally Advanced/Metastatic Solid Tumors SIM0686 - Locally Advanced Solid Tumors | Phase 1 | Recruiting | Jiangsu Simcere Pharmaceutical Co., Ltd. | 220 | 2025-05-20 | 2025-07-03 |
| A Phase I Study of SIM0388 in Participants With Malignant Ascites. SIM0388 - Malignant Ascites | Phase 1 | Recruiting | Jiangsu Simcere Pharmaceutical Co., Ltd. | 50 | 2025-04-24 | 2025-06-06 |
| Study of SIM0508 Alone and in Combination in Patients With Advanced Solid Tumors SIM0508 Tablets, SIM0508 in combination with olaparib - Advanced Solid Tumors | Phase 1 | Recruiting | Jiangsu Simcere Pharmaceutical Co., Ltd. | 130 | 2024-12-06 | 2025-01-07 |
| A Study of SIM0270 Combined With Everolimus vs. Treatment of Physician's Choice in Patients With ER+/HER2- Advanced Breast Cancer (SIMRISE) SIM0270, Everolimus (Afinitor®), Exemestane tablets - Locally Advanced or Metastatic Breast Cancer | Phase 3 | Active not recruiting | Jiangsu Simcere Pharmaceutical Co., Ltd. | 482 | 2024-11-14 | 2026-08-11 |
| Mass Balance Clinical Trial of SIM0270 [14C] SIM0270 Oral Preparation - Healthy Participants | Phase 1 | Active not recruiting | Jiangsu Simcere Pharmaceutical Co., Ltd. | 6 | 2024-10-17 | 2024-11-27 |
| Efficacy and Safety of First-line Treatment for Extensive-stage Small Cell Lung Cancer Using a Combination Therapy of Trilaciclib, Envafolimab, Etoposide, and Carboplatin Chemotherapy （Etoposide and Carboplatin）, Immunotherapy （Envafolimab）, Trilaciclib - Lung Cancer, Small Cell | Phase 2 | Recruiting | Shanghai Chest Hospital | 52 | 2024-10-13 | 2024-11-21 |
| Evaluate the Effects of Food on the Pharmacokinetics of SIM0270 SIM0270 - Healthy Participants | Phase 1 | Completed | Jiangsu Simcere Pharmaceutical Co., Ltd. | 16 | 2024-07-23 | 2024-12-02 |
| Study of SIM0500 Alone in Participants With Relapsed or Refractory Multiple Myeloma SIM0500 - Relapsed or Refractory Multiple Myeloma | Phase 1 | Recruiting | Jiangsu Simcere Pharmaceutical Co., Ltd. | 130 | 2024-05-24 | 2026-08-28 |
| the Prevention of Bone Marrow Suppression Caused by Chemotherapy in Advanced NSCLC With Trilaciclib Trilaciclib - Non-small Cell Lung Cancer | Phase 2 | Enrolling by invitation | Henan Cancer Hospital | 41 | 2024-04-02 | 2026-01-28 |
Showing 20 of 87. Sign in to see all of them.
Arthritis, Rheumatoid (7) · Carcinoma, Non-Small-Cell Lung (5) · Ischemic Stroke (4) · Small Cell Lung Carcinoma (4) · COVID-19 (3) · Colorectal Neoplasms (3) · Multiple Myeloma (3) · Breast Neoplasms (2) · Lung Neoplasms (2) · Neoplasms (2) · Ovarian Neoplasms (2) · Pleural Effusion, Malignant (2) · Brain Edema (1) · Brain Neoplasms (1) · CADASIL (1)
endostar protein (8) · Carboplatin (6) · Cisplatin (6) · Injections (5) · Ritonavir (5) · SIM0417 (5) · iguratimod (5) · trilaciclib (5) · Docetaxel (3) · Methotrexate (3) · Abatacept (2) · Dexamethasone (2) · Drug Therapy (2) · Edaravone (2) · Endostatins (2)
China (81) · United States (3)
Wei Zhao (4) · Feng Bi, MD (2) · Xiaodong Jiang, MD (2) · Yongjun Wang, MD (2) · Yumei Yang (2) · Bijoyesh Mookerjee, MD (1) · Chen Wang (1) · Chunde Bao, MD (1) · Daiyuan Ma, M.D (1) · Dayi Hu, MD (1) · Huang Dingzhi, Ph.D (1) · Jia Chen, MD (1) · Jieruo Gu, Doctor (1) · Jin Li, Doctor (1) · Jin Li, MD (1)
PMID 40965470, PMID 33588596, PMID 30017831, PMID 31191007, PMID 31709115, PMID 33783067, PMID 34307140, PMID 34327344, PMID 34487721, PMID 37484496, PMID 37783378, PMID 38231624, PMID 39056160, PMID 39299559, PMID 39883265, PMID 40557879